Comparative Pharmacology
Head-to-head clinical analysis: BYQLOVI versus TAZORAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYQLOVI versus TAZORAC.
BYQLOVI vs TAZORAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.
Tazarotene is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RAR-β, RAR-γ) with high affinity, modulating gene expression involved in cell proliferation, differentiation, and inflammation.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.
Apply a pea-sized amount to affected areas once daily in the evening. Tazorac is available as a 0.05% or 0.1% gel or cream. For plaque psoriasis, the 0.1% gel is typically used. For acne, the 0.1% cream or gel is started, then decreased to 0.05% if irritation occurs.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life of tazarotenic acid is approximately 18 hours (range 7-30 hours) after topical application, allowing once-daily dosing; systemic exposure is low due to extensive protein binding and slow clearance.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; fecal excretion is minimal (<5%).
Primarily fecal: approximately 60-70% eliminated in feces (as metabolites), renal excretion accounts for <10% as unchanged drug and metabolites, with <1% as unchanged tazarotenic acid.
Category C
Category C
Topical Retinoid
Topical Retinoid